MOR earnings

– Entered into Business Combination Agreement to be acquired by Novartis for € 68.00 per share in cash, representing a total equity value of € 2.7 billion – Received all mandatory antitrust approvals for the proposed acquisition by Novartis – Shareholder acceptance period for the Novartis offer has commenced and will end on May 13, 2024, at 24:00 hours CEST – Sold all tafasitamab rights worldwide to Incyte – € 631.9 million in cash and other financial assets as of March 31, 2024 MorphoSys AG ((FSE: MOR, NASDAQ:MOR) reports results for the first quarter of 2024. "The proposed acquisition by Novartis is advancing steadily, and we continue to anticipate its closure in the first hal

– Entered into Business Combination Agreement to be acquired by Novartis for € 68.00 per share in cash or € 2.7 billion equity value – Sold all tafasitamab rights worldwide to Incyte – Presented comprehensive Phase 3 MANIFEST-2 study results at ASH 2023 Annual Meeting, demonstrating pelabresib improves all four disease hallmarks of myelofibrosis – Monjuvi® U.S. net product sales of US$ 24.1 million (€ 22.4 million) for the fourth quarter of 2023 and US$ 92.0 million (€ 85.0 million) for the full year of 2023 – € 680.5 million in cash and other financial assets as of December 31, 2023 – MorphoSys to host conference call and webcast on Thursday, March 14, 2024, at 1:00 pm CET (12:00

Conference Call AlertPLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 7, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the financial year 2023 on March 13, 2024, at 09:00 pm CET (08:00 pm GMT; 04:00 pm EDT).MorphoSys' Management team will host a conference call and webcast on March 14, 2024, at 01:00 pm CET (12:00 pm GMT; 08:00 am EDT) to present the results for the financial year 2023 and provide an outlook for 2024.The conference call will start with a presentation by the Management team followed by a Q&A session.A live webcast and slides will be made available in the Investors section of the MorphoSys' website, www.morphosys.com.To join the conference call via pho

Tafasitamab sold to IncyteNovartis to launch a voluntary public takeover offer for all MorphoSys shares at a price of € 68.00 per share in cashShareholders benefit from attractive premium of 94 percent to the one-month volume weighted average price before January 25, 2024Novartis provides ample resources to maximize and accelerate pelabresib's potential on a global scaleMorphoSys' Management Board and Supervisory Board unanimously support both agreementsMorphoSys to host conference call and webcast on Tuesday, February 6, 2024 at 02:00 pm CET (01:00 pm GMT; 08:00 am EST)PLANEGG and MUNICH, GERMANY / ACCESSWIRE / February 5, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced the compan

Pelabresib and ruxolitinib combination significantly reduced spleen size, with an SVR35 response rate nearly double that of placebo plus ruxolitinib Showed a strong positive trend in reducing symptom burden and a twofold increase in patients achieving both SVR35 and TSS50 versus placebo plus ruxolitinib Improved measures of anemia, including higher hemoglobin response rates, fewer patients requiring transfusions and fewer anemia adverse events versus placebo plus ruxolitinib Improved bone marrow fibrosis by at least one grade in more patients versus placebo plus ruxolitinib Demonstrated safety results consistent with prior clinical trials, with fewer grade ≥3 adverse events compared

MANIFEST-2 met primary endpoint, nearly doubling SVR35 response rate (66% versus 35%) The key secondary endpoints assessing symptom reduction, TSS50 and absolute change in TSS, showed significant improvements for intermediate-risk patients (p<0.05, p<0.02, respectively) and strong numerical improvements for overall population Pelabresib plus ruxolitinib showed clinically meaningful anemia improvement versus placebo and ruxolitinib Safety results were consistent with prior clinical trials, with no new safety signals MorphoSys intends to submit for approval in the U.S. and Europe in mid-2024 Company to host conference call and webcast on Tuesday, November 21, at 2:00 p.m. CET (1:00

– Phase 3 MANIFEST-2 topline results expected by the end of November, with detailed findings in oral presentation at ASH 2023 – Monjuvi® U.S. net product sales of US$ 23.4 million (€ 21.5 million) for the third quarter of 2023 – U.S. FDA granted Fast Track designation for tulmimetostat in ARID1A-mutated endometrial cancer – € 642.2 million in cash and other financial assets as of September 30, 2023 Conference call and webcast (in English) tomorrow, November 16, 2023, at 2:00 pm CET (1:00 pm GMT/8:00 am ET) MorphoSys AG ((FSE: MOR, NASDAQ:MOR) reports results for the third quarter and the first nine months of 2023. "With pelabresib, MorphoSys has the potential to meaningfully imp

Conference Call AlertPLANEGG and MUNICH, GERMANY / ACCESSWIRE / November 9, 2023 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the third quarter and first nine months 2023 on November 15, 2023, at 10:00 pm CET (09:00 pm GMT; 04:00 pm EST).MorphoSys' Management team will host a conference call and webcast on November 16, 2023, at 02:00 pm CET (01:00 pm GMT; 08:00 am EST) to present the results for the third quarter and first nine months 2023 and provide an outlook for the remainder of the year.The conference call will start with a presentation by the Management team followed by a Q&A session.A live webcast and slides will be made available in the Investors section of the M

Preliminary Q3 2023 Monjuvi U.S. net product sales of US$ 23.4 million (€ 21.5 million)Preliminary Gross Margin for Monjuvi U.S. net product sales for Q3 2023 of 65%Anticipate full year 2023 Monjuvi U.S. net product sales to be US$ 85-95 million and full year gross margin for Monjuvi U.S. net product sales to be approximately 75%MUNICH, GERMANY / ACCESSWIRE / October 25, 2023 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today reported preliminary Monjuvi® U.S. Net Product Sales and Gross Margin for the third quarter of 2023 and provided an update to its financial guidance for 2023.Preliminary Monjuvi® (tafasitamab-cxix) U.S. Net Product Sales are US$ 23.4 million (€ 21.5 million) for the third quart

– Monjuvi® U.S. net product sales of US$ 23.6 million (€ 21.7 million) for the second quarter of 2023 – Enrollment of Phase 3 MANIFEST-2 study of pelabresib in first-line myelofibrosis is complete, with topline data expected by the end of 2023 – Phase 3 studies frontMIND of tafasitamab in first-line diffuse large B-cell lymphoma and inMIND of tafasitamab in relapsed/refractory follicular lymphoma or marginal zone lymphoma are fully enrolled – € 672.8 million in cash and other financial assets as of June 30, 2023 Conference call and webcast (in English) tomorrow, August 10, 2023, at 2:00pm CEST (1pm BST/8:00am EDT) MorphoSys AG ((FSE: MOR, NASDAQ:MOR) reports results for the second

– Monjuvi® U.S. net product sales of US$ 20.8 million (€ 19.4 million) for the first quarter of 2023 – Enrollment of Phase 3 MANIFEST-2 study of pelabresib in first-line myelofibrosis is complete, with topline data expected by the end of 2023 – Enrollment of Phase 3 frontMIND study of tafasitamab in first-line diffuse large B-cell lymphoma is complete – € 791.5 million in cash and other financial assets as of March 31, 2023  Conference call and webcast (in English) tomorrow, May 04, 2023, at 2:00pm CEST (1:00pm BST/8:00am EDT) MorphoSys AG ((FSE: MOR, NASDAQ:MOR) reports results for the first quarter of 2023. "We had a strong first quarter, marked by numerous achievements. Most

Conference Call AlertMUNICH, GERMANY / ACCESSWIRE / April 27, 2023 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the first quarter 2023 on May 3, 2023 at 10:00 pm CEST (09:00 pm BST; 04:00 pm EDT).MorphoSys' Management team will host a conference call and webcast on May 4, 2023 at 02:00 pm CEST (01:00 pm BST; 08:00 am EDT) to present the results for the first quarter 2023 and provide an outlook for 2023.The conference call will start with a presentation by the Management team followed by a Q&A session.A live webcast and slides will be made available at the Investors section on MorphoSys' website, www.morphosys.com.To join the conference call via phone, participants may pr

– Topline data from the Phase 3 MANIFEST-2 study expected in early 2024 – Monjuvi® U.S. net product sales of US$ 25.3 million (€ 24.7 million) for the fourth quarter of 2022 and US$ 89.4 million (€ 84.9 million) for the full year of 2022 – € 907.2 million in cash and other financial assets as of December 31, 2022 – Conference call and webcast (in English) tomorrow, March 16, 2023, at 1:00pm CET (12:00pm GMT/8:00am EDT) MorphoSys AG ((FSE: MOR, NASDAQ:MOR) reports results for the fourth quarter and the full year 2022. "2022 was a defining year for MorphoSys. We made advances in our pipeline by progressing our Phase 3 clinical trials, including pelabresib in myelofibrosis and tafasitamab

Conference Call AlertPLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 9, 2023 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the financial year 2022 on March 15, 2023 at 09:00 pm CET (08:00 pm GMT; 04:00 pm EDT).MorphoSys' Management team will host a conference call and webcast on March 16, 2023 at 01:00 pm CET (12:00 pm GMT; 8:00 am EDT) to present the results for the financial year 2022 and provide an outlook for 2023.The conference call will start with a presentation by the Management team followed by a Q&A session.A live webcast and slides will be made available at the Investors section on MorphoSys' website, www.morphosys.com.To join the conference call via phone, par

– Monjuvi® U.S. net product sales of US$ 22.2 million (€ 21.9 million) for the third quarter of 2022 – Presentation of preliminary results from phase 1/2 study of tulmimetostat (CPI-0209) supporting its potential application in a broad array of advanced tumors – Enrollment advances in MANIFEST-2 phase 3 trial for pelabresib in myelofibrosis – € 1,038.1 million in cash and other financial assets as of September 30, 2022 Conference call and webcast (in English) tomorrow, November 17, 2022, at 2:00pm CET (1pm GMT/8:00am ET) MorphoSys AG ((FSE: MOR, NASDAQ:MOR) reports results for the third quarter and the first nine months of 2022. "As we approach the end of this year, I am proud of what

Conference Call AlertPLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 10, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the third quarter and first nine months 2022 results on November 16, 2022 at 10:00 pm CET (9:00 pm GMT; 4:00 pm EST).MorphoSys' Management team will host a conference call and webcast on November 17, 2022 at 2:00 pm CET (1:00 pm GMT; 8:00 am EST) to present the third quarter and first nine months financial results 2022 and provide an outlook for 2022.The conference call will start with a presentation by the Management team followed by a Q&A session.A live webcast and slides will be made available at the Investors section on MorphoSys' website, www.mo

MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022Preliminary Q3 2022 Monjuvi U.S. net product sales of US$ 22.2 million (€ 21.9 million)Anticipated full year 2022 Monjuvi U.S. net product sales of approximately US$ 90 millionPLANEGG / MUNICH, GERMANY / ACCESSWIRE / October 21, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today reported preliminary Monjuvi® U.S. net product sales for the third quarter of 2022 and provided an update to its financial guidance for 2022.Preliminary Monjuvi ® (tafasitamab-cxix) U.S. Net Product Sales are US$ 22.2 million (€ 21.9 million) for the third quarter of 2022 and US$ 64.1 million (€ 60.2 million) for the first ni

– Monjuvi® U.S. net product sales of US$ 23.3 million (€ 21.7 million) for the second quarter 2022, a 25% Q-Q growth and 29% Y-Y growth – Efficacy and safety data of pelabresib for potential treatment improvement in myelofibrosis presented at EHA Congress 2022 – Entered into collaboration with Pfizer and Incyte for a combination study of Monjuvi and TTI-622, a Fusion Protein Directed Against CD47 – Updated financial guidance published on July 26, 2022 Conference call and webcast (in English) tomorrow, August 4, 2022, at 2:00pm CEST (1pm BST/8:00am EDT) MorphoSys AG ((FSE: MOR, NASDAQ:MOR) reports results for the second quarter and first half year of 2022. "In the second quarter of 202

Conference Call AlertPLANEGG and MUNICH, GERMANY / ACCESSWIRE / July 28, 2022 / MorphoSys AG (FSE:MOR); (NASDAQ:MOR) will publish its results for the second quarter and first half year 2022 results on August 3, 2022 at 10:00 pm CEST (9:00 pm BST; 4:00 pm EDT). MorphoSys' Management team will host a conference call and webcast on August 4, 2022 at 2:00 pm CEST (1:00 pm BST; 8:00 am EDT) to present the second quarter and first half year financial results 2022 and provide an outlook for 2022. The conference call will start with a presentation by the Management team followed by a Q&A session.A live webcast and slides will be made available at the Investors section on MorphoSys' website, www.morp

Preliminary Q2 2022 Monjuvi U.S. net product sales of US$ 23.3 million (€ 21.7 million)Update of financial guidance range for 2022 Monjuvi U.S. net product sales (now US$ 90 to US$ 110 million)Update of R&D expense guidance (now € 275 to € 300 million) following license agreements for felzartamab and MOR210PLANEGG/MUNICH, GERMANY / ACCESSWIRE / July 26, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today reported preliminary U.S. net product sales of Monjuvi® (tafasitamab-cxix) for the second quarter 2022 and announced an update of its financial guidance for 2022 based on the preliminary unaudited consolidated results for the first six months 2022 and following the license agreements with Human

Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014Preliminary Q2 2022 Monjuvi U.S. net product sales of US$ 23.3 million (€ 21.7 million)Update of financial guidance ranges for 2022 Monjuvi U.S. net product sales (now US$ 90 to US$ 110 million), R&D expenses (now € 275 to € 300 million) and SG&A expenses (now € 150 to € 165 million)PLANEGG/MUNICH, GERMANY / ACCESSWIRE / July 26, 2022 / MorphoSys AG (FSE: MOR)(NASDAQ:MOR) announces today an update of its financial guidance for 2022, after preliminary completion of the latest evaluation of MorphoSys' half year 2022 financial performance.MorphoSys updates its financial guidance based on the

– Monjuvi® U.S. net product sales of US$ 18.7 million (€ 16.6 million) for the first quarter 2022, a 21% year-over-year growth – NCCN® updated the designation of Monjuvi to preferred regimen in its Clinical Practice Guidelines in Oncology for B-cell Lymphoma – Pipeline advances: enrollment progressing across three Phase 3 trials in myelofibrosis, first-line DLBCL, and FL/MZL – € 846.9 million in cash and other financial assets at March 31, 2022 Conference call and webcast (in English) tomorrow, May 5, 2022, at 2:00pm CEST (1pm GMT/8:00am EDT) MorphoSys AG ((FSE: MOR, NASDAQ:MOR) reports results for the first quarter 2022. "Our clinical pipeline has never been stronger as it is today.

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / April 28, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the first quarter 2022 on May 4, 2022 at 10:00 pm CEST (9:00 pm GMT; 4:00 pm EDT).MorphoSys' Management team will host a conference call and webcast on May 5, 2022 at 2:00 pm CEST (1:00 pm GMT; 8:00 am EDT) to present results for the first quarter 2022 and provide an outlook for 2022.The conference call will start with a presentation by the Management team followed by a Q&A session.A live webcast and slides will be made available at the Investors section under "Upcoming Events & Conferences" on MorphoSys' website, http://www.morphosys.com.Dial-in number for the conference c

– Monjuvi® U.S. net product sales of US$ 23.6 million (€ 20.5 million) for the fourth quarter and US$ 79.1 million (€ 66.9 million) for the full year 2021 – Pipeline advances: enrollment progressing across three Phase 3 trials in myelofibrosis, first-line DLBCL, and FL/MZL – Results of the ongoing MANIFEST Phase 2 study of pelabresib in combination with ruxolitinib for myelofibrosis suggest potential benefit and disease modifying characteristics of pelabresib – € 976.9 million in cash and other financial assets at December 31, 2021 Conference call and webcast (in English) tomorrow, March 17, 2022, at 1:00pm CET (12pm GMT/8:00am EDT) MorphoSys AG ((FSE: MOR, NASDAQ:MOR) reports results

Conference Call AlertPLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 10, 2022 / MorphoSys AG (FSE:MOR);(NASDAQ:MOR) will publish its results for the financial year 2021 on March 16, 2022 at 9:00 pm CET (8:00 pm GMT; 4:00 pm EDT).MorphoSys' Management team will host a conference call and webcast on March 17, 2022 at 1:00 pm CET (12:00 pm GMT; 8:00 am EDT) to present results for the financial year 2021 and provide an outlook for 2022.The conference call will start with a presentation by the Management team followed by a Q&A session.A live webcast and slides will be made available at the Investors section under "Upcoming Events & Conferences" on MorphoSys' website, http://www.morphosys.com.Dia

Monjuvi U.S. net product sales of US$ 22.0 million (€ 18.6 million), 22% growth Q-QTen abstracts, including two oral presentations, accepted at upcoming ASHPelabresib data for arm 3 of MANIFEST study to be presented at ASH confirm prior dataFelzartamab demonstrated proof-of-concept in patients with aMN at Kidney WeekPLANEGG / MUNICH, GERMANY / ACCESSWIRE / November 11, 2021 / MorphoSys AG ((FSE: MOR, NASDAQ:MOR) reports financial results for the third quarter and the first nine months of 2021."Monjuvi sales continued to build momentum in the third quarter where we saw a broadening of the prescriber base and increased utilization in second-line patients," said Jean-Paul Kress, M.D., Chief Exe

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 2, 2021 / MorphoSys AG (FSE:MOR); (NASDAQ:MOR) today announces that revenues from product sales of Monjuvi (R) (tafasitamab-cxix) in the U.S. amount to € 18.6 million (US$ 22 million) for the third quarter of 2021 and € 46.4 million (US$ 55.5 million) for the first nine months of 2021. Monjuvi (R) is being co-commercialized by Incyte and MorphoSys in the United States.MorphoSys will publish its full results for the first nine months and third quarter 2021 on November 10, 2021 at 10:00pm CET (4:00pm EST).MorphoSys' Management Board will host a conference call and webcast on November 11, 2021 at 2:00pm CET (8:00am EST) to present the first nine m

- Monjuvi U.S. net product sales of € 14.9 million (US$ 18.0 million), 16% growth Q-Q- MorphoSys announced and subsequently completed its acquisition of Constellation Pharmaceuticals- Announced and closed ~US$ 2.0 billion strategic funding partnership with Royalty Pharma- Updated group financial guidance- Conference call and webcast (in English) tomorrow, July 29, 2021, at 2:00pm CEST (1:00pm BST/8:00am EDT)PLANEGG/MUNICH, GERMANY / ACCESSWIRE / July 29, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) reports financial results for the second quarter and the first half year of 2021."We regained the momentum in Monjuvi sales as we exited the second quarter and are encouraged to see that momentum con

PLANEGG, GERMANY and MUNICH, GERMANY / ACCESSWIRE / July 21, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR), a commercial-stage biopharmaceutical company and a leader in antibody and protein technologies, will publish its results for the second quarter and first half 2021 on July 28, 2021 at 10:00pm CEST (4:00pm EDT).MorphoSys' Management Board will host a conference call and webcast on July 29, 2021 at 2:00pm CEST (8:00am EDT) to present the second quarter and first half financial results 2021 and provide a further outlook for 2021.The conference call will start with a presentation by the Management Board followed by a Q&A session. Following Board Members will be on the call:Jean-Paul Kress, M.D

MonjuviU.S. net product sales of € 12.9 million (US$ 15.5 million)Tremfya royalties of € 11.6 millionReaffirming group revenue guidance of € 150 to € 200 millionConference call and webcast (in English) tomorrow, May 6, 2021 at 2:00pm CEST (1:00pm BST/8:00am EDT)PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 5, 2021 / MorphoSys AG ((FSE:MOR, NASDAQ:MOR) reports financial results for the first quarter of 2021."For 2021, our focus is on three key areas: executing on the Monjuvi launch; rapidly advancing the tafasitamab backbone strategy through additional clinical studies; and expanding our pipeline," said Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys. "While we experienced headwinds